Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy
ACS Pharmacology & Translational Science · 10.05.2024 · 7 (5) · 1395-1403
DOI: 10.1021/acsptsci.4c00035 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 29.04.2024. Verfasst von Ryotaro Onoue und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fusion Oriented REsearch for disruptive Science and Technology.
Abstract (Originalsprache)
Auger electron therapy and photodynamic therapy (PDT) have attracted attention as powerful anticancer modalities. Herein, we report the development of novel bimodal agents for Auger electron therapy and PDT, and their application to combination therapy. [125I]NBH-1/NBH-1 and [125I]NBH-2/NBH-2, composing Hoechst and iodostyryl-BODIPY, were synthesized and evaluated regarding their usefulness as bimodal agents. [125I]NBH-1 showed significantly higher nuclear uptake than [125I]NBH-2 and radioactivity-dependent cytotoxicity induced by Auger electrons. In addition, NBH-1 exhibited photoinduced cytotoxicity. Combination therapy using [125I]NBH-1 and NBH-1 with light irradiation induced a superior cytotoxicity to these treatments alone. In tumor-bearing mice injected with NBH-1 or [125I]NBH-1/NBH-1 under light irradiation, significant tumor growth inhibition was observed compared with that of the control group. Especially, [125I]NBH-1/NBH-1 under light irradiation showed the strongest therapeutic effects among all treatments. These results suggest that [125I]NBH-1/NBH-1 is a potent bimodal agent for Auger therapy and PDT and that combination therapy using [125I]NBH-1 and NBH-1 shows enhanced therapeutic efficacy.
Autor:innen und Institutionen
- Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
ORCID-Profile: Hiroyuki Watanabe, Masahiro Ono
Förderung
- Fusion Oriented REsearch for disruptive Science and Technology
Zitieren
APA
Onoue, R., Watanabe, H., & Ono, M. (2024). Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy. ACS Pharmacology & Translational Science, 7(5), 1395-1403. https://doi.org/10.1021/acsptsci.4c00035
Vancouver
Onoue R, Watanabe H, Ono M. Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy. ACS Pharmacology & Translational Science. 2024;7(5):1395-1403. doi:10.1021/acsptsci.4c00035
BibTeX
@article{Onoue2024,
author = {Onoue, Ryotaro and Watanabe, Hiroyuki and Ono, Masahiro},
title = {Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy},
journal = {ACS Pharmacology & Translational Science},
year = {2024},
volume = {7},
number = {5},
pages = {1395--1403},
doi = {10.1021/acsptsci.4c00035}
}
EUVIMED